<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04284761</url>
  </required_header>
  <id_info>
    <org_study_id>CP-001</org_study_id>
    <nct_id>NCT04284761</nct_id>
  </id_info>
  <brief_title>A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer</brief_title>
  <acronym>Biolen-PC</acronym>
  <official_title>A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alessa Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alessa Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biolen, a novel implant, is intended to deliver an anti-androgen locally to the prostate
      gland for the management of prostate disease, while minimizing systemic exposure and its
      associated side-effects. The objectives of the study are to assess whether the Biolen is
      safe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, multi-center, single-arm feasibility study is planned to assess the safety
      and patient tolerance of Biolen for the localized delivery of bicalutamide into the prostate
      in patients presenting for treatment of prostate cancer. Study participants will have
      placement of the drug eluting Biolen and be followed through scheduled radical prostatectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Biolen bicalutamide implant</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by number and incidence of adverse events</measure>
    <time_frame>change from baseline to radical prostatectomy up to 12 weeks after implantation</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in prostate size</measure>
    <time_frame>change from baseline to radical prostatectomy up to 12 weeks after implantation</time_frame>
    <description>prostate measurement by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in tumor size</measure>
    <time_frame>change from baseline to radical prostatectomy up to 12 weeks after implantation</time_frame>
    <description>tumor measurement by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Prostate Specific Antigen (PSA)</measure>
    <time_frame>change from baseline to radical prostatectomy up to 12 weeks after implantation</time_frame>
    <description>PSA level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Biolen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biolen bicalutamide implant. Single implantation. In situ until prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Bicalutamide implant</intervention_name>
    <description>Biolen bicalutamide implant</description>
    <arm_group_label>Biolen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate.

          -  Study participant qualified and planning for radical prostatectomy.

          -  At least 1 prostate lesion measurable by MRI &gt; 0.5 cm within one month of screening.

          -  PSA &gt; 3 ng/mL within 3 months of screening.

          -  Gleason score 3+4 or higher.

          -  Study participant must be willing to undergo post-treatment imaging by MRI.

          -  ECOG performance status 0 or 1.

        Exclusion Criteria:

          -  Prior radiotherapy or surgery for prostate cancer.

          -  Prior or ongoing hormonal therapy for prostate cancer.

          -  Prior prostate procedures such as transurethral resection of the prostate,
             transurethral microwave thermotherapy of the prostate, high-intensity focused
             ultrasound or minimally invasive BPH procedure.

          -  Study participant unwilling or unable to undergo MRI, including patients with
             contra-indications to MRI, such as cardiac pacemakers, non-compatible intracranial
             vascular clips, etc.

          -  Metallic hip implant or any other metallic implant or device that distorts the quality
             of prostatic MR images.

          -  Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months
             of screening or total use within the last two years prior to screening of &gt; 3 months.

          -  Presence of any metastatic disease.

          -  Prostate volume more than 80 cc at prior MRI imaging.

          -  I-PSS score &gt;20.

          -  History of prostate infection.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Munster, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alessa Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peggy McLaughlin</last_name>
    <phone>6505048501</phone>
    <email>pmclaughlin@alessatherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Munster, MD</last_name>
    <email>pamela.munster@alessatherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Australian Clinical Trials</name>
      <address>
        <city>Wahroonga</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Ombler</last_name>
      <phone>+61 2 9473 8765</phone>
      <email>research@urologist.net.au</email>
    </contact>
    <investigator>
      <last_name>Henry Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wollongong</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Chin, MD</last_name>
      <phone>02 42716644</phone>
      <email>docpete@docpete.com</email>
    </contact>
    <investigator>
      <last_name>Peter Chin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Australian Urology Associates</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Moon</last_name>
      <phone>0421345698</phone>
    </contact>
    <contact_backup>
      <last_name>Ashley Baring</last_name>
      <email>abaring@aua.com.au</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Moon</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Grummet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

